R Squared Ltd Lowers Stake in Boston Scientific Corporation $BSX

R Squared Ltd trimmed its holdings in Boston Scientific Corporation (NYSE:BSX) by 67.6% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 9,963 shares of the medical equipment provider’s stock after selling 20,754 shares during the period. R Squared Ltd’s holdings in Boston Scientific were worth $625,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in BSX. FWL Investment Management LLC acquired a new position in Boston Scientific in the 2nd quarter valued at about $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific during the 4th quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC purchased a new position in shares of Boston Scientific in the 4th quarter valued at approximately $26,000. Bangor Savings Bank grew its stake in shares of Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares during the last quarter. Finally, Board of the Pension Protection Fund acquired a new position in shares of Boston Scientific in the fourth quarter valued at approximately $29,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE:BSX traded up $0.69 on Tuesday, reaching $45.29. 4,761,435 shares of the company were exchanged, compared to its average volume of 18,170,854. The company has a 50-day moving average of $50.99 and a 200-day moving average of $69.27. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The firm has a market cap of $67.31 billion, a price-to-earnings ratio of 18.94, a price-to-earnings-growth ratio of 0.86 and a beta of 0.58. Boston Scientific Corporation has a 1-year low of $42.25 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts forecast that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a stock buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

Insider Activity

In other news, Director David C. Habiger purchased 2,250 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the purchase, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Edward J. Ludwig purchased 3,580 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders purchased 9,800 shares of company stock worth $554,012. Company insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on BSX. Jefferies Financial Group decreased their price target on Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a report on Wednesday, June 24th. Piper Sandler restated an “overweight” rating and issued a $65.00 target price on shares of Boston Scientific in a research note on Friday, June 12th. Wolfe Research downgraded shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. Stifel Nicolaus dropped their price target on shares of Boston Scientific from $75.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, June 25th. Finally, Robert W. Baird set a $70.00 price target on shares of Boston Scientific in a report on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $82.12.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.